Novo Holdings discloses 5.1% stake in Obsidian

Novo Holdings A/S, a Danish life sciences investment firm wholly owned by Novo Nordisk Foundation, reports a significant position in Obsidian Therapeutics, Inc. common stock.

Rhea-AI Filing Summary

Novo Holdings A/S, a Danish life sciences investment firm wholly owned by Novo Nordisk Foundation, reports a significant position in Obsidian Therapeutics, Inc. common stock. Novo Holdings beneficially owns 3,123,992 shares of Obsidian common stock, representing 5.1% of the outstanding class.

Novo Holdings has sole voting and sole dispositive power over all 3,123,992 shares and no shared voting or dispositive power. The Novo Nordisk Foundation, despite owning Novo Holdings, is stated as not deemed to have beneficial ownership of these Obsidian securities under the disclosed governance structure.

Key Figures

Beneficial ownership: 3,123,992 shares Percent of class: 5.1% Sole voting power: 3,123,992 shares +2 more

5 metrics

Beneficial ownership 3,123,992 shares Common stock of Obsidian Therapeutics, Inc. reported by Novo Holdings A/S

Percent of class 5.1% Portion of Obsidian common stock class held by Novo Holdings A/S

Sole voting power 3,123,992 shares Shares over which Novo Holdings A/S has sole power to vote or direct the vote

Sole dispositive power 3,123,992 shares Shares over which Novo Holdings A/S has sole power to dispose

Par value $0.001 per share Par value of Obsidian Therapeutics, Inc. common stock

Key Terms

beneficial ownership, sole voting power, dispositive power, Schedule 13G, +1 more

5 terms

beneficial ownership financial

"Amount beneficially owned: 3,123,992 (b) Percent of class: 5.1%"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"Sole power to vote or to direct the vote: 3,123,992"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 3,123,992"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"form_type": "SCHEDULE 13G""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

commercial foundation financial

"Novo Nordisk Foundation, a Danish commercial foundation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Obsidian Therapeutics (OBX) shares does Novo Holdings A/S own?

Novo Holdings A/S beneficially owns 5.1% of Obsidian Therapeutics’ common stock. This stake corresponds to 3,123,992 shares over which Novo Holdings has sole voting and dispositive power, with no shared control reported.

How many Obsidian Therapeutics (OBX) shares are reported by Novo Holdings A/S?

Novo Holdings A/S reports beneficial ownership of 3,123,992 Obsidian Therapeutics common shares. It has sole voting and sole dispositive power over all these shares, and reports no shared voting or dispositive authority.

Who is the reporting owner in this Schedule 13G for Obsidian Therapeutics (OBX)?

The reporting owner is Novo Holdings A/S, a Danish investment firm focused on life sciences and finance. It is wholly owned by Novo Nordisk Foundation but states that the Foundation is not deemed a beneficial owner of these Obsidian shares.

Does Novo Nordisk Foundation directly own Obsidian Therapeutics (OBX) shares in this filing?

The filing states that, based on the governance structure, Novo Nordisk Foundation is not deemed to have beneficial ownership of Obsidian shares. Novo Holdings A/S is the entity that holds and reports the 3,123,992 shares.

What voting rights does Novo Holdings A/S report for its Obsidian Therapeutics (OBX) stake?

Novo Holdings A/S reports sole voting power over 3,123,992 shares of Obsidian and no shared voting power. It also reports sole dispositive power over the same number of shares with no shared dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/10/2026 - 04:21 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Obsidian Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

67448A106

(CUSIP Number)

08/03/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 67448A106

1

Names of Reporting Persons

Novo Holdings A/S

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,123,992.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,123,992.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,123,992.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Obsidian Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1030 Massachusetts Avenue, Cambridge, MA, 02138.
Item 2.
(a)	Name of person filing: Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novozymes A/S (also known as Novonesis A/S), and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
(b)	Address or principal business office or, if none, residence: Tuborg Havnevej 19 2900 Hellerup, Denmark
(c)	Citizenship: Denmark
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 67448A106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,123,992
(b)	Percent of class: 5.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,123,992
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,123,992
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Holdings A/S

Signature:	Barbara Fiorini
Name/Title:	Barbara Fiorini, General Counsel, Finance & Operations
Date:	08/10/2026